Company: MDCXW
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001062993-25-008292
Chunk: 11

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-01
Form: DRS
Chunk 11
---
, Inc.

Our website address is www.medicuspharma.com. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase our securities.

<div align='center'>- 3 -</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

Standby Equity Purchase Agreement

On February 10, 2025, we entered into the SEPA with the Selling Shareholder. Pursuant to the SEPA and subject to the satisfaction of certain conditions, the Selling Shareholder has committed to purchase our common shares in increments (each purchase, an "Advance") up to an aggregate gross sales price of up to $15,000,000 during the 36 months following the date of the SEPA. The common shares will be sold at our option pursuant to the SEPA at 97% of the Market Price (as defined pursuant to the SEPA) and purchases are subject to certain limitations set forth in the SEPA. The Company reserves the right to set a minimum acceptable price in connection with any Advance. The total number of common shares issuable under the terms of the SEPA is limited to a number equivalent to 19.99% of the outstanding common shares as of the date of the SEPA, or 2,362,163 common shares, unless certain pricing conditions are met, which could have the effect of limiting the total proceeds made available to us under the SEPA. The issuance of common shares under the SEPA is subject to further limitations, including that the common shares beneficially owned by Selling Shareholder and its affiliates at any one time will not exceed 4.99% of the then-outstanding common shares. As consideration for the Selling Shareholder's commitment to purchase common shares pursuant the SEPA, we paid the Selling Shareholder a structuring fee in the amount of $25,000 and issued to Selling Shareholder the Commitment Shares. See "Standby Equity Purchase Agreement".

Recent Developments

Update on Phase 2 Clinical Study

On April 21, 2025, the Company announced that the Institutional Review Board approved the increase in the number of patients in its SKNJCT-003 Phase 2 clinical study from 60 to 90. The clinical study will expand from the nine clinical sites in the United States to include